NCT07153172View on ClinicalTrials.gov

Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108

PHASE1RecruitingINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

September 15, 2027

Study Completion Date

September 15, 2027

Conditions
Obesity
Interventions
DRUG

INV-347

Participants who were dosed with INV-347 in the First In Human study INV-CL-108 and still have measurable plasma exposure of INV-347 are included to assess long term safety.

Trial Locations (1)

G1P 0A2

RECRUITING

Syneos Health, Québec

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT07153172 - Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108 | Biotech Hunter | Biotech Hunter